Interestingly, Fzd6 is downregulated in GC tissue samples and cell lines, and overexpression of Fzd6 was able to suppress both the proliferation and migration of GC [60], thus Fzd6 would not be a viable therapeutic target for GC. This evidence concerns the gene FZD6 and gastric cancer.